Latest news and research on all cancers and treatments, updated several times a week
VolitionRx Chief Executive Officer Cameron Reynolds, said, "Pancreatic cancer is the fourth leading cause of cancer deaths in the developed world ...
Receiving "orphan drug" designation from the U.S. Food and Drug Administration (FDA) for the Company's pancreatic cancer treatment, with ...
The risk of stroke was highest among patients with lung, pancreatic and colorectal cancers, which are often diagnosed at advanced stages. Stroke risk ...
The drug, PEGPH20, being tested against pancreatic cancer, has the potential to help treat several other types of solid tumor cancers, its chief ...
The UNSW researchers, who published their findings in the journal Oncotarget, found that beta III-tubulin is highly expressed in pancreatic cancer ...
Patients with new cases of cancer face a heightened risk of stroke in the ... common malignant cancer types — as well as pancreatic cancer because ...
RX-3117 was also evaluated in a primary low passage Champions Tumorgraft mo del derived from biopsy samples from pancreatic cancer patients ...
Uprising
“Most types of cancer can be put down to bad luck rather than risk factors ... for Cancer Research, The Lustgarten Foundation for Pancreatic Cancer ...
Twice in the past year, Adaptive Biotechnologies raised a truckload of cash. The first time, the company invested in its cutting-edge immune system ...
Warde junior forward Giacomo Brancato was recently diagnosed with Non-Hodgkins Lymphoma, a cancer that strikes the body's auto-immune system.
“For our big multinational phase-III prostate cancer trial we have hired ... surface to the T cells of the immune system, acting as messengers between ...
The death of popular sportscaster Stuart Scott was linked to cancer, after being ... A healthy person's immune system is strong to fight cancer and a ...
Immunotherapy will define new era of GU cancer care ... that harnesses the power of the immune system to fight and reject the patient's own cancer.
“Laboratory studies have found that mistletoe kills cancer cells and stimulates the immune system. “The use of mistletoe to treat cancer has been ...
An Australian biotechnology company has contributed to a world-first diagnostic test for bladder cancer that could save patients a lot of pain and ...
The company said that these genetic alterations are implicated in the pathogenesis and progression of bladder cancer and other solid tumor types, ...
The most common type of bladder cancer is known as urothelial carcinoma (UC) and accounts for approximately 90% of all bladder cancers.
Mirati Therapeutics Doses First Patient in Phase 2 Study of Mocetinostat in Bladder Cancer ... -MarketWatch
Mirati Therapeutics (MRTX) Doses First Patient In Phase 2 Study Of Mocetinostat In Bladder ... -biospace.com
The Miriam Hospital is using a new minimally invasive technology that improves the ability for doctors to detect bladder cancer. Using blue-light ...
"Drs. Bunn and de Vere White offer leadership in lung, prostate and bladder cancer diagnosis, treatment, and monitoring. We are honored that both ...
... causes 86% of lung cancer, 65% of oesophageal cancer, 37% of bladder cancer and 29% of pancreatic cancer), poor diet (51% of stomach cancer ...
... of bacillus Calmette-Guérin (BCG) into the bladder for the treatment of superficial bladder cancer, and BCG is all about local immunotherapy.
Today's market up move notwithstanding, nano cap Advaxis (ADXS +15.8%) enjoys continued buying from cancer immunotherapy-loving investors.
Celsion Corporation (Celsion), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, ...
These engineered T cells derive from Kite's proprietary autologous cell therapy (eACT) platform along with Amgen's wide-ranging selection of cancer ...
Seattle-based Adaptive, a spinoff from the Fred Hutchinson Cancer ... of the leading names in cancer immunotherapy, such as Bristol-Myers Squibb, ...
Cancer and infectious disease immunotherapy developer Argos Therapeutics is collaborating with Saint-Gobain's Performance Plastics division, ...
ACR Appropriateness Criteria® Postradical Prostatectomy Irradiation in Prostate Cancer
The purpose of this article is to present an updated set of American College of Radiology consensus guidelines formed from an expert panel on the appropriate use of radiation therapy in postprostatectomy prostate cancer.
The purpose of this article is to present an updated set of American College of Radiology consensus guidelines formed from an expert panel on the appropriate use of radiation therapy in postprostatectomy prostate cancer.
Practice & Policy
What We Can Learn From Our Patients
Patient satisfaction data can give practices insight into their operations and make specific, practice-level adjustments accordingly, and with aggregated data we can gain insights into global practice responsiveness and patient perceptions regarding care.
Patient satisfaction data can give practices insight into their operations and make specific, practice-level adjustments accordingly, and with aggregated data we can gain insights into global practice responsiveness and patient perceptions regarding care.
Clinical Quandaries
Base of the Skull Metastases in Metastatic Castration-Resistant Prostate Cancer
A 63-year-old man with no family history of prostate cancer underwent annual screening with serum prostate-specific antigen (PSA) testing. His PSA level was under 3 ng/mL 2 years earlier. A year and a half ago he developed lower urinary tract symptoms (urgency and frequency) and had a PSA level of 18 ng/mL. A prostate biopsy revealed 9 out of 12 cores involved with prostatic adenocarcinoma, mostly Gleason score 5+4=9. On rectal examination he had a fixed prostate; he was not a candidate for surgery. A bone scan revealed no evidence of metastatic disease. Magnetic resonance imaging of the pelvis showed involvement of the prostate and three lymph nodes.
A 63-year-old man with no family history of prostate cancer underwent annual screening with serum prostate-specific antigen (PSA) testing. His PSA level was under 3 ng/mL 2 years earlier. A year and a half ago he developed lower urinary tract symptoms (urgency and frequency) and had a PSA level of 18 ng/mL. A prostate biopsy revealed 9 out of 12 cores involved with prostatic adenocarcinoma, mostly Gleason score 5+4=9. On rectal examination he had a fixed prostate; he was not a candidate for surgery. A bone scan revealed no evidence of metastatic disease. Magnetic resonance imaging of the pelvis showed involvement of the prostate and three lymph nodes.
Tambahkan Komentar